AKT1 and neoplasm: Furthermore, characterizing the tumor microenvironment of LMS might point to combined approaches to facilitate an immune-response such as immune-checkpoint inhibitors with metabolic factors (e.g. Indoleamine-pyrrole 2,3-dioxygenase (IDO1) inhibitors), targeted therapy (PI3K-AKT inhibitors) and other strategies.